KPV vs LL-37

Side-by-side comparison of KPV, LL-37 — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute KPV KPV (Lys-Pro-Val) — Alpha-MSH Tripeptide Recovery LL-37 LL-37 (Human Cathelicidin Antimicrobial Peptide) Recovery
Basics
Molecular type Alpha-MSH C-terminal TripeptideHuman Cathelicidin
Amino acids 337
Molecular weight 355.4 Da4,493.3 Da
Half-life Short (hours)Short (hours)
Route(s) Subcutaneous, Oral (GI conditions), TopicalSubcutaneous, Topical, Intranasal
Mechanism & Research
Primary mechanism KPV binds melanocortin receptors (MC1R and MC3R) expressed on immune cells, epithelial cells, and neurons. Receptor activation suppresses NF-κB-mediated pro-inflammatory cytokine production (TNF-α, IL-6, IL-8) and drives… LL-37 disrupts microbial membranes through electrostatic interaction — its cationic amphipathic helical structure inserts into negatively charged bacterial membranes, causing lethal membrane permeabilisation. This mechan…
Research status Research Compound Research Compound
Evidence summary KPV has robust preclinical data for inflammatory bowel conditions (Crohn's disease, ulcerative colitis models) and wound healing. Oral nanoparticle formulations have been developed to improve colonic delivery. LL-37 has been studied extensively for wound healing, respiratory infections (including COVID-19 lung immunity), and more recently for senolytic applications. Its broad antimicrobial and immunomodulatory profile makes it…
Protocol & Dosing
Typical dose 500 mcg–2 mg/day (SC); variable oral dosing1–5 mg per injection or topical application
Frequency Once or twice dailyDaily
Duration 4–8 weeks4–8 weeks
Timing Any time; pre-meals for GI applicationsAny time
Safety
Common side effects
  • Injection site redness (SC)
  • Mild skin darkening (possible — MC1R activity)
  • Headache (rare)
  • Injection site pain (cytokine release)
  • Mild erythema
  • Headache (rare)
Contraindications
  • Known melanocortin sensitivity
  • Pregnancy (insufficient data)
  • Active melanoma (MC1R concern)
  • Autoimmune conditions (immune stimulation)
  • Active lupus (LL-37 is a lupus autoantigen in some patients)
  • Pregnancy (no data)
Anti-doping Not Prohibited Not Prohibited
Deeper reading
Related peptides BPC-157, LL-37, TB-500 BPC-157, GHK-Cu, KPV
Full profile Read full KPV profile → Read full LL-37 profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.